Immunoassay of s-adenosylmethionine using analogs thereof and personalized therapeutics

A method for determining a cancer therapy regimen for treating a tumor in a patient comprising:

• (a) determining the methylation index in a patient sample;
• (b) comparing the level of methylation index obtained to a control methylation index to determine whether the level of said index is a predictive marker;
• and b) determining a cancer therapy regimen for treating the tumor based on the methylation index values, wherein the methylation index values are indicative that the patient is either a responsive patient or a non-responsive patient. ??

A method for diagnosing in a subject, or predicting the susceptibility of a subject to, a mental or neurodegenerative disorder, the method comprising:

• (a) obtaining one or more biological samples from the subject;
• (b) determining the levels of S-adenosylmethionine or the methylation index associated with said sample;
• and (c) comparing the levels of the biomarkers determined in (b) with the levels of said biomarkers from one or more control samples, wherein abnormal levels of the two or more biomarkers in the sample(s) from the subject compared to the one or more control samples is predictive of susceptibility of the subject to a mental or neurodegenerative disorder.

A method of personalized medicine for mammal diseases, the method comprising measuring the methylation index in body fluids from a subject having a disease, and proposing a treatment with a likelihood of being effective for said subject based on the methylation index levels in said body fluids.

A method for monitoring the efficacy of a cancer treatment in a patient diagnosed with comprising determining the methylation index level in the patient at a first point in time;

• treating the patient with a cancer treatment;
• determining the methylation index level in the patient at a second point in time;
• and comparing the level(s) of the methylation index in the subject at the first point in time with the levels at the second point in time to determine the efficacy of the cancer treatment.